Other Stories

EU criticizes UK's rapid approval of Pfizer-BioNTech's COVID-19 vaccine Updated: 2020-12-03 10:04:53 KST

The U.K. is set to begin distribution of Pfizer and BioNTech's COVID-19 vaccine as soon as next week.
This comes as the British government on Wednesday, granted authorization following months of clinical trials conducted by the Medicines and Healthcare Products Regulatory Agency.

"The vaccine will begin to be made available across the UK from next week. I would like to pay tribute to and to thank all those who have made this possible."

The Joint Committee on Vaccination and Immunisation has also announced the specifics of the people who will be given first priority for the vaccination.

"Residents in care homes for older adults and care home workers are the highest priority. Following that are people aged 80 years and above, alongside front-line healthcare and social care workers."

However, Britain's swift move was seen as unreasonable by many.
The European Medicines Agency have bluntly criticized the UK's rapid approval of COVID-19 vaccines.
The agency, responsible for the EU's COVID-19 vaccines approval, said its own procedure was more "appropriate",… as the longer process is based on more evidence and thorough examinations.
An EU lawmaker has also been explicit in criticizing Britain by referring to the vaccine approval as "hasty emergency marketing authorization".
In response, the UK's medicines regulator insisted that "no corners have been cut", reassuring the public that the vaccine is safe for use.

"The public can be absolutely confident that every rigorous check has been done to reach the judgement that we reached, that the benefits far outweigh any risk."

Meanwhile, updates on Pfizer and BioNTech's vaccine authorization in the U.S. will potentially be made by December 10th and December 29th in Europe.
Choi Min-jung, Arirang News.
KOGL : Korea Open Government License
본 저작물 중 본문에 해당하는 뉴스 스크립트(텍스트)는 공공누리 제1유형-출처표시 조건에 따라 이용할 수 있습니다.